BridgeBio Pharma, Inc. (BBIO) stock
Close on Nov 11, 2026Market cap $15.49BP/E –Yield –
BridgeBio Pharma, Inc. grew revenue 167.3% to $945.54M over the twelve months to Sep 30, 2026. Free cash flow was -$369.81M. At the latest close the market valued the company at $15.49B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $15.49B
- P/E ratio
- –
- Price to sales
- 16.39
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -2.39%
Fundamentals
- Revenue
- $945.54M
- EPS, diluted
- -$3.04
- Free cash flow
- -$369.81M
- Book value per share
- -$8.48
- Diluted shares
- 196M
Trading
- Next earnings
- Feb 23, 2027 (estimated, after the close)
- Previous close
- $78.67
- Open
- $78.86
- Day's range
- $77.80 – $79.75
- Volume
- 2,324,968
- Average volume (20 days)
- 3,105,491
- Index membership
- Russell 1000 (since Jun 2026), Russell 3000
- Beta (5 years)
- 1.12
- 52-week range
- $62.06 – $93.42
- RSI (14 days)
- 69.6
- Volatility (1 year)
- 44.5%
- Relative volume
- 0.83×
- WACC
- 10.5%
Index membership is inferred from the holdings of funds that track each index (IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | BBIO | S&P 500 | Difference | BBIO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +21.7% | -2.4% | +24.1 pts | ||
| 3 months | -5.0% | -1.2% | −3.8 pts | ||
| Year to date | +4.0% | +12.3% | −8.3 pts | ||
| 1 year | +19.5% | +12.4% | +7.0 pts | ||
| 3 years | +193.5% | +78.8% | +114.7 pts | +43.2% | +21.4% |
| 5 years | +66.1% | +75.2% | −9.0 pts | +10.7% | +11.9% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
EPS, diluted
Free cash flow
Press releases
Releases BridgeBio Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- News
- News
- Results
About BridgeBio Pharma
Pharmaceutical Preparations
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and delivering treatments for patients with genetic diseases and significant unmet medical needs. Operating through a decentralized hub-and-spoke model, the company organizes program-specific development units supported by centralized operational and regulatory infrastructure. Its primary commercial product is acoramidis, a small molecule transthyretin stabilizer branded as Attruby in the United States and Beyonttra internationally for transthyretin amyloid cardiomyopathy. The enterprise also holds approved therapies such as Nulibry and advances late-stage clinical programs including infigratinib for skeletal conditions and encaleret for calcium regulation disorders. Its offerings serve patient populations diagnosed with rare genetic conditions through specialized medical treatment centers and healthcare practitioners.
Company profile, executives and historyBridgeBio Pharma stock: common questions
What is BridgeBio Pharma's stock price?
BBIO closed at $79.54 on Nov 11, 2026, up 1.11% on the day. Over the past 52 weeks it traded between $62.06 and $93.42.
What is BridgeBio Pharma's market cap?
BridgeBio Pharma was worth $15.49B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is BBIO's P/E ratio?
BridgeBio Pharma lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.04), so it has no meaningful P/E ratio.
How much revenue does BridgeBio Pharma make?
BridgeBio Pharma reported revenue of $945.54M for the twelve months to Sep 30, 2026, up 167.3% from a year earlier.
Does BridgeBio Pharma pay a dividend?
No. BridgeBio Pharma has not paid a cash dividend over the last twelve months.
When does BridgeBio Pharma report earnings next?
BridgeBio Pharma is expected to report Q4 FY2026 results on Feb 23, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has BBIO stock performed over the past year?
Including dividends, BBIO returned +19.5% over the past year, against +12.4% for the S&P 500.
How many BBIO shares are sold short?
21M shares were sold short at the latest FINRA report, 16.62% of the float, or 7.1 days of average trading volume.
Who are BridgeBio Pharma's competitors?
Companies most similar to BridgeBio Pharma by business, industry and size include KNSA, IONS, INSM, SRPT, PTCT.
See a number that looks wrong?